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Abstract
Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome caused by Coronavirus 2 (SARS-CoV-2). In
the light of its rapid global spreading, on 11 March 2020, the World Health Organization has declared it a pandemic.
Interestingly, the global spreading of the disease is not uniform, but has so far left some countries relatively less
affected. The reason(s) for this anomalous behavior are not fully understood, but distinct hypotheses have been
proposed. Here we discuss the plausibility of two of them: the universal vaccination with Bacillus Calmette–Guerin
(BCG) and the widespread use of the antimalarial drug chloroquine (CQ). Both have been amply discussed in the
recent literature with positive and negative conclusions: we felt that a comprehensive presentation of the data
available on them would be useful. The analysis of data for countries with over 1000 reported COVID-19 cases has
shown that the incidence and mortality were higher in countries in which BCG vaccination is either absent or has been
discontinued, as compared with the countries with universal vaccination. We have performed a similar analysis of the
data available for CQ, a widely used drug in the African continent and in other countries in which malaria is endemic;
we discuss it here because CQ has been used as the drug to treat COVID-19 patients. Several African countries no
longer recommend it officially for the fight against malaria, due to the development of resistance to Plasmodium, but
its use across the continent is still diffuse. Taken together, the data in the literature have led to the suggestion of a
possible inverse correlation between BCG immunization and COVID-19 disease incidence and severity.
Introduction
The coronavirus disease 2019 (COVID-19) was first
reported in Wuhan, China, in December 20191–3. Since
then, it has spread to most countries throughout the world,
with major outbreaks in the United States, Spain, Italy,
France, UK, Russia, China, South Korea, and Iran. On 11
March 2020, the World Health Organization (WHO)
declared the severe acute respiratory syndrome caused by
Coronavirus 2 (SARS-CoV-2) outbreak a global pandemic4.
According to general consensus, SARS-CoV-2 originated
from bats. There still is no conclusive indication on the
transmitting animal host: somehow, the virus adapted to
human hosts, rapidly spreading by human-to-human
transmission5–7. As of today, there is still no vaccine that
can protect against it. Specific anti-viral drugs that could
treat the infection have been proposed and tested in clinical
trials: the results have sometimes been promising, but not
conclusive. The outcomes of the numerous randomized
international clinical trials are about to appear and will
hopefully provide conclusive answers. One of them has just
appeared with positive results with remdesivir, an inhibitor
of the RNA polymerase of COVID-198.
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The available data on COVID-199 have revealed that the
disease incidence and mortality vary, even dramatically,
among countries. The variability could be due to a variety
of factors such as ethnicity, dietary habits, climate, social
activities, genetic differences, and governance structures.
Here we would like to add to the list two potential factors
that could possibly play a role in the susceptibility to the
infection and in its gravity: the use of chloroquine (CQ)
and the anti-tuberculosis (TB) vaccination (Bacillus
Calmette–Guerin, BCG). The reason for considering
them together in this contribution is that they are unique
in their general presence/use in the populations which the
COVID-19 pandemic has apparently so far only hit with
minor violence. Our analysis of COVID-19 data from
countries with universal BCG vaccination, discontinued
vaccination, and countries that never adopted BCG vac-
cination suggests that disease incidence and morbidity are
reduced in countries with universal BCG immunization
compared with those that have not adopted the vaccine.
The finding also applies to countries in which variables
such as climate, dietary habits, and genetic origin essen-
tially coincide. Suggestive examples are Spain and Por-
tugal: the incidence of COVID-19 and its fatalities are at
the time of writing this manuscript 386 per million
population in Spain, where BCG vaccination has never
been adopted, whereas, in the neighboring Portugal, in
which general BCG vaccination was adopted in 1965, the
disease incidence and mortality are 56 per million,
respectively9. Further analysis of age-related susceptibility
towards COVID-19 disease has revealed that countries
with universal vaccination exhibit reduced disease inci-
dence in all age groups. Countries that discontinued
vaccination appear to exhibit disease incidence at levels
intermediate between vaccinated and unvaccinated
countries. There were significant differences in mortality
in all age groups between the vaccinated and unvacci-
nated countries, although there were no differences
between the unvaccinated countries and those that have
discontinued vaccination.
The matter of CQ, a powerful regulator of endosomal
pH in autophagy10–13 and cell death14,15, affecting distinct
cell function16,17 and survival18,19, and of its derivative
hydroxychloroquine (HCQ)20, has peculiar aspects: they
are widely used in patients affected by the COVID-19
disease and reports from hospitals and doctors who treat
patients frequently suggest beneficial effects. However,
major medical institutions tend to recommend a cautious
use, also pointing at dangerous side effects. In the absence
of large-scale randomized trials, the effects on patients are
frequently seen with significant doses of skepticism, which
could also be motivated by the fact that HCQ is con-
sistently used in late stages of the disease, when it would
be too late to see its possible effects. This is an important
point, because apart from their role in COVID-19
patients, which will be hopefully settled by the rando-
mized trials now under way, here the presentation will
focus on the possible chemoprophylactic properties of CQ
and HCQ. It is common knowledge that shortages in their
availability are recently being experienced in several
countries that have not (yet) been hit by the full force of
the pandemic. At the beginning of March, the Indian
Council of Medical Research, under the Ministry of
Health and Family Welfare, has recommended chemo-
prophylaxis with HCQ for asymptomatic healthcare
workers who treat patients and for asymptomatic house-
hold contacts of confirmed COVD19 cases. It stated that
its use in prophylaxis “is derived from available evidence
of benefit as treatment and supported by preclinical data.”
A recent large-scale international trial on HCQ sponsored
by the WHO (the “Solidarity” trial) had produced negative
results, prompting the WHO to interrupt it21. However,
the trial itself has been severely criticized by a panel of
180 scientists and thus suggested to be invalid22. As a
result of the criticism, WHO has actually decided to
resume the trial.
Results and discussion
The Mycobacterium bovis BCG strain was developed in
1921 at the Pasteur Institute through attenuation by serial
passages of an M. bovis strain isolated from a cow with
tubercular mastitis23. This strain was subsequently dis-
tributed to several laboratories in the world and a number
of additional strains were then developed24. The six major
BCG strains, namely Pasteur 1173 P2, Danish 1331, Glaxo
1077 (derived from the Danish strain), Tokyo 172-1,
Russia BCG-I, and Moreau RDJ, now account for >90% of
the BCG vaccines employed worldwide25. As five different
strains of BCG were employed in different countries, we
analyzed their correlative efficacy in protecting against
COVID-19. Our data have shown that mixed and JAPAN
strains seem superior to the DANISH strain. BCG exhibits
efficacy against disseminated TB and meningitis in
childhood26,27; currently, ~100 million children are vac-
cinated every year worldwide. However, the vaccine
exhibits poor efficacy against adult pulmonary TB and
several countries have, therefore, discontinued BCG
immunization23. Subsequently, BCG was shown to exhibit
protective effects against leprosy, buruli ulcer, and several
other diseases, including those not associated with
mycobacteria28,29. BCG is a potent immunomodulator,
especially of the cell-mediated immunity, and is employed
for the treatment of cancers such as that of the bladder30.
It is actually being tested for several other cancers31.
Recently, BCG was shown to exhibit efficacy against type I
diabetes32. This was first shown in mice in Edmonton in
1993, which also partially protects against sepsis and
respiratory infections when given following early
infection33.
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To investigate the impact of BCG vaccination on the
spread of COVID-19, we first classified countries into
three groups following the data obtained from BCG
ATLAS (“The BCG World Atlas” http://www.bcgatlas.
org/index.php) till 29 May 2020. These three groups
represent (i) countries that never adopted a national BCG
vaccination program, (ii) countries that had a mass BCG
vaccination program but discontinued it, and (iii) coun-
tries with an active national BCG immunization policy.
We then extracted incidence and mortality of COVID-19
cases from the updated (up to 29 May 2020) data from the
website of the Worldometer.info9. We selected countries
with at least 1000 confirmed cases of COVID-19 (further
details of the criteria for selection of countries are pro-
vided in the “Materials and Methods” section). The
numbers of infections and deaths in these countries vary
dramatically and cannot be compared directly, as the
population sizes of these countries also vary (see Table 1).
Therefore, we estimated the number of cases per million
capita and presented the normalized measurements in
Fig. 1 for the incidence and mortality, respectively. The
results in Fig. 1a show that countries without a universal
BCG policy (such as Belgium, Italy, the United States, and
the Netherlands) have increased incidence of COVID-19
(2810.9 ± 497.1 (mean ± SEM) per million) compared with
countries with ongoing national BCG policy (570.9 ±
155.6 (mean ± SEM) per million). The incidence for
countries that discontinued BCG vaccination was inter-
mediate between these two groups (1844.67 ± 508.89
(mean ± SEM) per million). In terms of morbidity, the
countries with a universal BCG policy exhibited (see
Fig. 1b) the lowest number of deaths due to COVID-19
(92.4 ± 34.7 (mean ± SEM) per million), which is sig-
nificantly lower than that for countries that discontinued
universal BCG vaccination (104.5 ± 33.6 (mean ± SEM)
per million) (p= 0.001, Mann–Whitney U-test). Coun-
tries with no BCG vaccination were most profoundly
affected (186.1 ± 56.8 (mean ± SEM) per million). These
results are in line with two previous reports34.
This type of analysis does not reflect the true impact of
BCG against COVID-19. For example, a country with a
higher percentage of population of elderly people may
Table 1 List of countries with total number of incident and death cases in COVID-19 as of 29 May 2020.
Universal BCG immunization Discontinued universal BCG immunization
Country Population Total cases Total deaths Country Population Total cases Total deaths
Germany 83,761,616 1,83,294 8600
China 1,439,323,776 83,001 4634 UK 67,855,909 272,826 38,376
India 1,378,826,256 182,990 5188 France 65,261,548 188,625 28,771
Indonesia 273,271,317 26,473 1613 Spain 46,753,295 286,308 27,125
Pakistan 220,497,647 69,496 1483 Canada 37,713,606 90,190 7073
Brazil 212,430,296 498,440 105,557 Australia 25,473,913 7195 103
Japan 126,507,477 16,804 886 Czechia 10,707,339 9233 319
Turkey 84,259,813 163,103 4515 Sweden 10,093,917 37,113 4395
Iran 83,897,889 151,466 7797 Israel 9,197,590 17,024 284
Thailand 69,785,445 3081 57 Austria 9,002,048 16,731 668
S. Korea 51,265,561 11,468 270 Denmark 5,790,499 11,633 571
Poland 37,849,973 23,686 1064 Finland 5,540,010 6859 320
Saudi Arabia 34,765,118 83,384 480 Norway 5,417,605 8437 236
Malaysia 32,329,329 7819 115 Non-vaccinated
Romania 19,247,736 19,257 1262 Country Population Total cases Total deaths
Chile 19,102,061 94,858 997 USA 330,838,184 1,816,897 1,05,557
Ecuador 17,619,020 38,571 3334 Italy 60,469,020 232,664 33,340
Greece 10,427,085 2915 175 Netherlands 17,131,732 46,257 5951
Portugal 10,199,093 32,203 1396 Belgium 11,585,389 58,381 9467
Singapore 5,846,395 34,884 23 Switzerland 8,649,211 30,862 1920
Ireland 4,932,957 24,929 1651 Iceland 341,055 1806 10
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report more deaths than a country with a relatively
younger population, simply because of increased comor-
bidities that worsen disease severity. Unfortunately, not
enough public data are available to analyze the impact of
such confounding factors. We therefore further probed
how the incidence and mortality varies among different
age groups in a population. We considered five different
age groups, namely: <15, 15–44, 45–64, 64–79, and over
80 years of age. The results in Fig. 1c represent the dis-
tribution of disease incidence among different age groups
for the three different types of countries. We also plotted
the mean incidence of cases as a function of the different
age groups for the three types of countries in Fig. 1d. The
results indicate three significant features as follows: (i) the
disease incidence is very low for subjects <15 years of age
and does not show significant dependence on the pre-
sence or absence of universal BCG vaccination policies.
This is possibly due to high resistance of young people to
symptomatic disease. (ii) The number of infected cases
across the age groups is always higher for countries
without universal BCG vaccination policy. (iii) The dif-
ferences between countries with universal BCG vaccine
policy and countries without such a policy increase and
reach their peak for age groups 45–64 and 65–79 years.
The difference in the number of confirmed cases in these
age groups is ~550–600 per million of the population
between countries with vs. without universal BCG vacci-
nation policy. The reduction in disease incidence seems
significant for countries without universal BCG vaccina-
tion policy, where the number of confirmed cases per
million is quite high for the younger age groups. The
consistently reduced disease incidence across all age
groups for countries with a universal BCG policy is in line
with the suggestion of an inverse correlation between the
BCG vaccine and COVID-19. In comparison, a rise in
disease incidence across all age groups for countries
Fig. 1 Impact of BCG immunization on incidences of COVID19. a and b represent the number of incident and deaths per million ofpopulation
across countries employing continuous universal vaccination, some that have discontinued vaccination, and some that never adopted
BCGvaccination. c Age specific incident cases per million of population for these three types of countries. d Age specific mean number of incident
cases permillion along with standard deviations are presented for different types of countries.
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without a universal BCG policy substantiates the
hypothesis that BCG immunization could be repurposed
to provide a weapon to combat the COVID-19 pandemic.
In fact, very recently several countries, including the
United States, Australia, Germany, and the Netherlands
have initiated a BCG vaccination project aiming at the
control COVID35,36. An intermediate level of protection
for countries that have discontinued universal BCG vac-
cination policy further corroborates our claim.
Having found that countries with universal BCG vac-
cination policy perform better in limiting the spread of
COVID-19 compared with countries without a universal
BCG vaccination or with countries that discontinued it,
we next explored the association between BCG vaccina-
tion and COVID-19 mortality for different age groups.
The result of our analysis is presented in the scattered
plots of Fig. 2a, b, in which the mean number of deaths
per million as a function of age groups is plotted for the
three different types of countries. The results show that
the distribution of fatal cases per million of people across
different age groups for countries without mass vaccina-
tion and countries with discontinued mass vaccination are
not significantly different (p= 0.41, Mann–Whitney U-
test). With increasing age, the death toll increases for
countries without or discontinued BCG vaccination pro-
grams. In comparison, the mortality is quite consistent and
rises only slightly in the elderly population. Differences in
the death toll between countries with or without a national
BCG program thus suggest that BCG has a role in low-
ering the COVID-19 casualty by manifold. To verify the
generality of our claim, we further compared our results
based on the data collected till 6 April 2020 as presented in
the Supplementary Information. The similarities between
the previous results with the present one based on the data
collected till 29 May 2020 supports our observation.
Although our results indicate a correlation between
BCG vaccination and COVID-19 progression/mortality,
one should also note that the confirmed cases to death
ratio varies widely among the countries analyzed. This
might be due to different strains of BCG used in these
countries for an induced trained immunity. Figure 3a
represents the evolution of several attenuated BCG strains
and their timeline. To examine the potential effects of
different BCG strains we considered seven strains, namely
BCG-Russia, BCG-Denmark, BCG-Japan, BCG-Brazil,
and BCG-Pasteur including a locally produced BCG strain
and a mixed strain of BCG. We compared the number of
confirmed cases and deaths per million that occurred
within the populations that received different types of
BCG vaccine. Figure 3b, c represent bar plots, indicating
the incidence and mortality, respectively. We found that
countries adopting a mixture of different strains of the
BCG vaccine such as South Korea and the Philippines
reported a lower number of confirmed and fatal cases.
The BCG-Denmark and BCG-Russia strains correlated
poorly in terms of limiting the COVID-19 spread and
Fig. 2 Impact of BCG immunization on death toll due to COVID19. a Age specific death cases per million of population for countries employing
continuous universal vaccination, some that have discontinued vaccination, and some that never adopted BCG vaccination. b Age specific mean
numberof death cases per million along with standard deviations are presented for different types of countries.
Sharma et al. Cell Death and Disease          (2020) 11:516 Page 5 of 10
Official journal of the Cell Death Differentiation Association
casualty. Taken together, the bulk of the data of the
analysis appear to be compatible with a correlation
between BCG vaccination and susceptibility to COVID-19
disease. To this end, a discussion related to certain
countries, which have performed very differently com-
pared with other countries. is essential One such example
is Brazil. Even if it is a country with universal BCG vac-
cination policy, the number of deaths due to COVID-19 is
the highest among the countries with similar vaccination
strategy. This could be due to the use of the BCG-Brazil
strain, which has been found ineffective against COVID-
19 (see Fig. 3b). The case of Russia is probably similar, as
the BCG strain used in Russia is probably also not effec-
tive against the coronavirus. A country that has done
extremely well in restricting the COVID-19 spread is
Australia. Although Australia has dropped its BCG pro-
gram back in 1985, the number of incident and deaths due
to COVID-19 are very low. This could be due to very low
population density of Australia, which helped to restrict
the spread of the virus effectively. However, caution on
the BCG matter is still necessary: a recent report on a
significant number of passengers of the Diamond Princess
ship, who had recently become infected with COVID-19
has found no correlation37. Similarly, the BCG vaccine,
which is routinely administered to all newborns in Israel
and was administered to immigrants with unknown vac-
cination records, showed no statistically significant dif-
ference in the susceptibility to the COVID-19 infection38.
Although these two studies seem to impose a strict cau-
tionary note on the preventive use of BCG, it must be
noted that the latter study had been performed only on a
population of a specific age group in a country that had
used an unknown BCG strain (“The BCG World Atlas”
http://www.bcgatlas.org/index.php) in the period
1955–1982. The significance of the Israel study is thus
difficult to evaluate, in particular as certain BCG strains
are more effective against the COVID-19.
The possibility that the diffuse use of CQ and HCQ may
possibly have a chemoprophylactic role in the populations
that have so far been much less affected by the pandemic,
e.g., those of most African countries or of India, could not
be based on the accurate numerical analyses done for the
BCG vaccination. However, although highly circumstantial,
it should still be discussed, considering the still very diffuse
Fig. 3 Efficacy of BCG strain against COVID19. a Types of BCG strain. b Number of COVID19 confirmed and c deaths cases observed forvarious
BCG strains.
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consumption of CQ by populations in which malaria is still
endemic. CQ has been instrumental in controlling the
malaria tragedy, particularly its resurgence after the inter-
national ban on dichloro-diphenyl-trichloroethane, which
had largely eliminated it by exterminating the Anopheles
mosquito. Unfortunately, CQ therapy was compromised by
the widespread appearance of drug resistance, particularly
for Plasmodium falciparum: a threonine at position 76 of
the CQ resistance gene pfcrt being the marker for CQ
resistence39. As a result, following a recommendation of
the WHO at the end of last century, most African coun-
tries officially discontinued its use in the fight against
malaria, replacing it with artemisinin-based therapy. In a
short time, however, the cessation of drug pressure led to
the re-emergence of CQ-sensitive Plasmodia40: in Malawi,
the first African country that had discontinued the use of
CQ in 1993, by 2003 the mutant pfcrt gene was no longer
present and CQ-sensitive malaria had regained pre-
dominance, as confirmed by the full efficacy of the drug in
a clinical trial41. The pattern by which the resistance to CQ
emerged and then declined had a strong regional character,
with resistance emerging earlier in East Africa with respect
to West Africa (see also Fig. 4). The pattern reflected the
variation in the use of the drug but also reflected the degree
of acceptance of the recommended official policy by the
different African populations. The accurate analysis by
Fig. 4 Distribution of Chloroquine use in African Countries. a Distribution of Chloroquine usage in African Countries, with interval ofconfidence.
b Visualization of the data in panel A. c The map shows the occurrence of chloroquine resistance in the Plasmodium parasite, from darkblue
(resistance at high levels) to light blue (no resistance). Countries in cyan are devoid of any malaria, but in those countries, chloroquine
orhydroxychloroquine are still used for some autoimmune or inflammatory condition. Countries, where high chloroquine resistance occurs, are still
among thehighest consumers of chloroquine, notwithstanding the adverse recommendation by most health authorities.
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Frosch et al.40. shows the consumption of CQ does not
reflect the national policies of the African Countries.
Although it varies among them, it has generally remained
high (Fig. 4). Indirectly, this is also shown by recent con-
tracts of pharmaceutical Companies to provide some
African Countries with very large amounts of CQ and
HCQ, and by the fact that some African Countries have
initiated programs to produce them34,42. The situation is
not limited to Africa: many countries outside Africa,
including the United States, have reported short market
supply of CQ and HCQ, and countries that produce them
have banned their export. In India, the shortage of CQ has
been attributed to widespread self chemoprophylaxis in the
face of the COVID-19 pandemic43. However, caution
should be taken44, as observational clinical trials for HCQ
in COVID-19 patients was not associated with either a
greatly lowered or an increased risk of the composite end
point of intubation or death45 also in association with
azithromycin21,46 and in view of potential toxicity as well47.
On the other hand, as mentioned above, the negative
results of the “Solidarity” international trial on HCQ21 have
been indicated to be flawed. In any case, the “therapeutic”
effect would not concern the discussion in this contribu-
tion, as we are considering its possible prophylactic role.
Conclusions
In this study, we have presented the evidence available
in the literature that has led to the suggestion of the
possible effects of two factors, BCG vaccination and
exposure to CQ, on the susceptibility to the COVID-19
infection. BCG vaccination is known to operate through
the cell-mediated immunity that is important against
COVID-1948. Although originally intended for tubercu-
losis, BCG immunization does not provide satisfactory
results for the adult pulmonary disease, but confers partial
protection against various other diseases49. We have
presented the data, suggesting that the BCG immuniza-
tion correlates with lower incidence and gravity of the
COVID-19 disease across different countries, even when
the BCG immunization was performed in childhood.
Although the matter of CQ and HCQ does not have the
degree of numerical sophistication of BCG vaccination, it
still deserves to be considered. Unfortunately, the litera-
ture on CQ and HCQ has so far exclusively dealt with
their therapeutic role in patients affected by the COVID-
19 infection, frequently in its advanced stages. In this
contribution, we have instead emphasized the possible
chemoprophylactic role of CQ and HCQ: even if the
evidence for it is admittedly only circumstantial, such a
role should be tested in appropriately designed trials
Materials and methods
To determine an association between BCG vaccination
and COVID-19 disease incidence and mortality across
several age groups of different countries, we first classified
countries into three categories according to their
respective BCG vaccination policy. These three classifi-
cations are as follows: countries that never adopted uni-
versal BCG vaccination, countries that adopted a universal
BCG vaccination policy but subsequently discontinued it,
and countries that currently exercise universal BCG vac-
cination50. The data for BCG vaccination policy across
these countries were mapped using “The BCG World
Atlas” (http://www.bcgatlas.org/index.php). As in a pan-
demic such as corona, constructing a data set at a single
point in time may not be enough to capture its spread, we
prepared two sets as follows: (i) data taken till 06 April
and (ii) till 29 April 2020. The results based on the most
updated data are presented in the manuscript, whereas
similar analysis based on data till 06 April are given in the
associated Supplementary Information. Our aim was to
probe the number of incident and deaths due to COVID-
19 in these three types of countries among different age
groups. For this purpose, five age intervals were defined as
the population below the age of 15, 15–44, 45–64, 65–79,
and age above 80 years. Two types of comparative cross-
sectional studies were performed as follows: (i) to com-
pare the number of respective COVID-19 cases per mil-
lion in the defined age groups of three defined classes of
countries based on BCG policy; and (ii) to compare the
number of respective COVID-19 deaths per million in the
defined age groups of three defined classes of countries
based on BCG policy. To obtain sufficient statistical
power for data analysis, we only included countries with
at least 1000 confirmed COVID-19 cases. As the number
of cases reported in lower-income countries is very low
and likely due to underreporting, we only included
higher-income and middle-income countries as per the
World Bank classification using the World Bank
data (https://datahelpdesk.worldbank.org/knowledgebase/
articles/906519-worldbank-country-and-lending-groups).
We collected the coronavirus-related age-specific data of
COVID-19 cases and deaths of countries from various
sources (see Supplementary Materials). Two-tailed
Mann–Whitney U-test was performed to test whether
the two independent samples have the same distribution,
where the null hypothesis H0 (i.e., both the samples are
following the same distribution) was compared against an
alternative hypothesis H1 (i.e., both the samples are fol-
lowing a different distribution), with a significance level of
0.05 (95% confidence interval). The significance of the test
was governed by a p-value. A p-value below the level of
significance (p < 0.05) indicates rejection of the null
hypothesis51. Data were analyzed using R scripts.
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